- Home
- Equipment
- australasia
- prostatic
Show results for
Refine by
Prostatic Equipment Supplied In Australasia
10 equipment items found
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
Pivalate is the invention of Professor Eric Aboagye of Imperial College London: Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilises the early steps of fatty acid oxidation and is very stable; In comparison to the clinical standard in PET imaging, 18F-FDG in prostate and brain cancers, Pivalate showed superior imaging performance and was equally ...
Manufactured by:AllVascular Pty Ltd based inLeonards, AUSTRALIA
The Sniper can be used with the AVAS for Liver Isolated Oxaliplatin (LIOX) for patients with colorectal liver cancer or on its own to treat primary liver cancer with TACE or SIRT, benign prostate hyperplasia, and uterine ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel. ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of diverse physiological functions including proliferation and immune cell functions. Under prolonged stimulation, P2X7 can form a membrane pore that’s ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
Manufactured by:Avania based inBrunswick, AUSTRALIA
Look to Avania’s urology team for the precise expertise you need to conduct and advance your research. From feasibility studies and protocol design through post-approval, our team guides you while sharing our specialized urology ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
INOVIQ has the exclusive worldwide license for SubB2M - an engineered protein that binds to a unique sugar molecule called Neu5Gc which is only present in human cancers. In initial clinical studies, SubB2M has detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers. There is also evidence that ...